2004
Inflammation has been reported in numerous neurodegenerative disorders such as Parkinson’s disease, stroke and Alzheimer’s disease (AD). In AD, the (…)
Consulter
2004
Tissue-type plasminogen activator (tPA) has been involved in both physiological and pathological glutamatergic-dependent processes, such as synaptic plasticity, seizure, trauma, (…)
Consulter
2004
Tissue-type plasminogen activator (tPA) is available for the treatment of thromboembolic stroke in humans. However, adverse effects of tPA have (…)
Consulter
2005
Neurotrophins are a family of growth factors that attenuate several forms of pathological neuronal cell death and may represent a (…)
Consulter
2005
Despite uncontroversial benefit from its thrombolytic activity, the documented neurotoxic effect of tissue plasminogen activator (tPA) raises an important issue: (…)
Consulter
We have studied the functional repercussions of cerebrovascular abnormalities in transgenic mice overexpressing TGF-beta1. These mice develop Alzheimer’s disease-like vascular (…)
Consulter